ArticleFrontiers in medicine2025
Nursing management of pulmonary mucormycosis with skin damage secondary to amphotericin B colloidal dispersion: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mucormycosis is a catastrophic fungal infection in immunocompromised patients and has a high mortality rate. Amphotericin B colloidal dispersions have demonstrated clinical efficacy in the treatment of mucormycosis; however, there is limited literature on the management of severe skin damage secondary to the extravasation of amphotericin B colloidal dispersions. Case presentation: A 36-year-old diabetic woman with severe pulmonary mucormycosis developed skin damage on her left foot after 34 days of amphotericin B colloidal dispersion treatment via a peripheral vein. The medication was switched to a central vein, and nursing interventions, including silver alginate ion dressing and saline wet compress, successfully managed the injury. By day 155, the skin had completely healed with minimal residual pigmentation. Conclusion: This case report describes the management of a severe skin injury caused by amphotericin B colloidal dispersion extravasation in an immunocompromised patient, carried out by bedside nurses. Relevance for clinical practice: This study presents an effective management strategy for skin damage caused by amphotericin B colloidal dispersions extravasation, emphasizing timely intervention and optimizing care for patients receiving prolonged or high-dose therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.